Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2004, 40(11): 889
ISSN 1699-3993
Copyright 2004 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2004.40.11.872578
 
 
Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator
Papp, K.A.
 
 
Recent research has demonstrated that psoriasis is not the result of a keratinocyte disorder, as previously believed. Although the exact etiology has not been clearly defined, much data has accumulated to elucidate the role of the immune system, particularly T lymphocytes, in the pathogenesis of the disease. With this knowledge, a number of biologic therapies that specifically target key pathogenic events have been developed. Efalizumab, a recombinant humanized monoclonal IgG1 antibody, is a T-cell modulator approved for patients with moderate to severe chronic plaque psoriasis. This article reviews the role of T lymphocytes in psoriasis pathogenesis, the mechanism of efalizumab action, and the efficacy and safety data observed during the efalizumab clinical trials.


Full Text: HTMLPDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy